Elanco (ELAN) CEO reports 129.2829 DSUs; holds 18,099.5935
Elanco Animal Health (ELAN): CEO Form 4 filing.
Rhea-AI Filing Summary
Elanco Animal Health (ELAN): CEO Form 4 filing. President, CEO and Director Jeffrey N. Simmons reported an acquisition of 129.2829 deferred stock units on 10/17/2025 (Transaction Code A). The filing shows a $21.42 price of the derivative security and a post‑transaction balance of 18,099.5935 deferred stock units held directly.
Each deferred stock unit represents the right to receive one share of common stock or the cash equivalent. These units settle in cash or shares following termination of employment or during a specified future year in accordance with the company’s Executive Deferral and Stock Match Plan.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Deferred Stock Units | 129.2829 | $21.42 | $3K |
Footnotes (2)
- F1. Each deferred stock unit represents the right to receive one share of Company common stock or the cash equivalent.
- F2. Deferred stock units settle in cash or shares of Company common stock following termination of employment or during a specified future year in accordance with Executive Deferral and Stock Match Plan.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Elanco (ELAN) report in this Form 4?
How many deferred stock units does the ELAN CEO hold after the transaction?
What is the price listed for the ELAN derivative security?
What do Elanco deferred stock units represent?
When do ELAN deferred stock units settle?
Who is the reporting person in this ELAN Form 4?
AI-generated analysis. How Rhea-AI works. Not financial advice.